Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case–Control Studies

**Laura E. Beane Freeman,**1,6* Manolis Kogevinas,**2,3,4,5* Kenneth P. Cantor,**1 Cristina M. Villanueva,**2,3,4,5* Ludmila Prokunina-Olsson,**6* Oscar Florez-Vargas,**4* Jonine D. Figueroa,**7,8 Mary H. Ward,**1 Stella Koutros,**1* Dalsu Baris,**1 Montserrat Garcia-Closas,**7* Molly Schwenn,**10* Allison Johnson,**11* Consol Serra,**3,5,12 Adonina Tardon,**3,13 Reina Garcia-Closas,**14 Alfredo Carrato,**15,16,17,18 Nuria Malats,**19,19* Margaret R. Karagas,**20* Nathaniel Rothman,**1* and Debra T. Silverman**1*

1Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, Maryland, USA
2Barcelona Institute for Global Health, Barcelona, Spain
3CIBER Epidemiología y Salud Pública, Madrid, Spain
4Universitat Pompeu Fabra (UPF), Barcelona, Spain
5Hospital del Mar Medical Research Institute, Barcelona, Spain
6Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, Maryland, USA
7Usher Institute, University of Edinburgh, Edinburgh, UK
8Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK
9Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, Maryland, USA
10Maine Cancer Registry, Augusta, Maine, USA
11Vermont Department of Health, Burlington, Vermont, USA
12Center for Research in Occupational Health, UPF, Barcelona, Spain
13Department of Preventive Medicine, Universidad de Oviedo, Oviedo, Spain
14Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
15Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
16Alcalá University, Madrid, Spain
17Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
18Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain
19Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain
20Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA

**BACKGROUND:** By-products are formed when disinfectants react with organic matter in source water. The most common class of disinfection by-products, trihalomethanes (THMs), have been linked to bladder cancer. Several studies have shown exposure–response associations with THMs in drinking water and bladder cancer risk. Few epidemiologic studies have evaluated gene–environment interactions for total THMs (TTHMs) with known bladder cancer susceptibility variants.

**OBJECTIVES:** In this study, we investigated the combined effect on bladder cancer risk contributed by TTHMs, bladder cancer susceptibility variants identified through genome-wide association studies, and variants in several candidate genes.

**METHODS:** We analyzed data from two large case–control studies—the New England Bladder Cancer Study \((n/n = 989 cases/1,162 controls)\), a population-based study, and the Spanish Bladder Cancer Study \((n/n = 706 cases/772 controls)\), a hospital-based study. Because of differences in exposure distributions and metrics, we estimated effects of THMs and genetic variants within each study separately using adjusted logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CI) with and without interaction terms, and then combined the results using meta-analysis.

**RESULTS:** Of the 16 loci showing strong evidence of association with bladder cancer, rs907611 at 11p15.5 [leukocyte-specific protein 1 (LSP1 region)] showed the strongest associations in the highest exposure category in each study, with evidence of interaction in both studies and in meta-analysis. In the highest exposure category, we observed OR = 1.66 (95% CI: 1.17, 2.34, \(p\)-trend = 0.005) for those with the rs907611-GG genotype and \(p\)-interaction = 0.02. No other genetic variants tested showed consistent evidence of interaction.

**DISCUSSION:** We found novel suggestive evidence for a multiplicative interaction between a putative bladder carcinogen, TTHMs, and genotypes of rs907611. Given the ubiquitous exposure to THMs, further work is needed to replicate and extend this finding and to understand potential molecular mechanisms. https://doi.org/10.1289/EHP9895

---

**Introduction**

Worldwide, bladder cancer ranks as the ninth most common incident cancer and the 13th in mortality, with ~400,000 cases diagnosed each year.1 Approximately 75% of incident cases occur in men. Several risk factors for bladder cancer have been identified, the most important of which is smoking.2 Other known or suspected risk factors include occupational exposures, diet, use of nonsteroidal anti-inflammatory drugs, and water contaminants, including arsenic, nitrate, and disinfection by-products (DBPs).2 DBPs are formed when organic constituents in source water react with chlorine or other disinfecting agents. Trihalomethanes (THMs), the most common of the DBPs, were first discovered in the 1970s,3 and hundreds of DBP species have since been identified.4 The types of by-products formed when water is treated depend on many factors, including the specific disinfection processes used (e.g., chlorination, ozonation, chloramination, use of chlorine dioxide), levels of naturally occurring organic material and anthropogenic compounds, and other characteristics of the raw water such as temperature, pH, and bromide concentration.4 Brominated compounds are formed when bromide levels in the source water are high, and reports from water utilities have
suggested increasing levels of brominated THMs in the United States. Three chemical classes of DBPs are regulated in the United States: total THMs (TTHMs) (chloroform, bromoform, bromodichloromethane, and chlorodibromomethane), haloacetic acids (HAAs), and oxahydrils; the European Union regulates bromate and TTHMs. The International Agency for Research on Cancer (IARC) has evaluated several individual DBPs, classifying some as possible [Group 2B; specifically chloroform, dichloroacetic acid, trichloroacetic acid, dibromoacetic acid, bromochloroacetic acid, and Mutagen X (MX; 3-chloro-4-(dichloromethyl)-5-hydroxy-5H-furan-2-one) or probable (Group 2A; specifically, chloral and chloral hydrate) human carcinogens. In addition, the National Toxicology Program (NTP) Report on Carcinogens recently classified six HAAs, bromochloroacetic acid, bromodichloroacetic acid, chlorodibromoacetic acid, dibromoacetic acid, dichloroacetic acid, and tribromoacetic acid, as reasonably anticipated to be human carcinogens. In its 2001 toxicological review of chloroform, the most common THM, the U.S. Environmental Protection Agency (EPA) noted that the majority of mutagenicity assays were negative and concluded that positive assays may have been an indirect consequence of cytotoxicity and cell regeneration in response to high exposures rather than a direct genotoxic effect. As reviewed by Richardson et al., although ingestion is important route of exposure, for some volatile chemicals, inhalation or dermal absorption may also be important. Brominated THMs have been shown to be mutagenic when activated by glutathione S-transferase theta 1 (GSTT1), in contrast to chloroform, which is not activated to a mutagen.

Early epidemiologic studies suggested that exposure to chlorinated drinking water was related to bladder cancer risk, an association that was confirmed in later studies, including the most recent meta-analysis. More detailed analyses have recently supported an exposure–response relationship between THM exposure and bladder cancer risk, as reviewed by Costet et al. Two case–control studies conducted in Spain and New England, USA, respectively, have suggested an exposure–response relationship between increasing exposure to THMs, and bladder cancer risk. Previous analyses from these two large case–control studies demonstrated evidence of gene–environment interactions for occupational exposures and smoking with known or suspected bladder cancer loci. Here, we evaluate interactions between bladder cancer loci and exposure to THMs in each of these two study populations.

**Methods**

**Study Population**

The two studies have been described. Briefly, in New England, cases included patients newly diagnosed with carcinoma of the urinary bladder between 2001 and 2004 among residents of Maine, New Hampshire, and Vermont and population controls, which were frequency matched to the cases by age at diagnosis/interview, sex, and state of residence (989 White cases and 1,162 White controls with complete exposure information and genotype data). The Spanish study included cases newly diagnosed with urothelial carcinoma of the bladder between 1998 and 2001 at 18 hospitals in five regions of Spain and hospital controls individually matched to the cases on age at diagnosis/interview, sex, and hospital (706 White cases and 772 White controls with complete exposure information and genotyping data). Characteristics of the two study populations included in this analysis are described in Table S1. The study protocols were reviewed and approved by the relevant institutional review boards and all participants provided signed, informed consent.

**Exposure Assessment**

Both studies relied on self-reported source of drinking water and historical measurement data to assign lifetime exposure to TTHMs, the compounds for which data were available to construct historical estimations. The specifics of the exposure assessment for each study are described below. In New England, a trained study interviewer visited participants’ homes and administered a computer-assisted personal interview (CAPI) that elicited information on a variety of factors, including global positioning system (GPS) coordinates of the current residence, and a lifetime residential history that was used to reconstruct lifetime water source information. We ascertained all jobs held for at least 6 months since the 16 years of age and the town of each workplace. We used self-reported water source (public, private well, other); for former residences and workplaces and assigned the most likely utility based on detailed methods as described by Nuckols et al. We obtained historical information from all utilities in the three study states plus Massachusetts from state and individual utility files, including measurement data, as well as source and treatment data. Outside the study states, we abstracted current water supply source type (ground/surface) from U.S. EPA and state databases and abstracted historical measurement data for the 22 states with the highest percentage of person-years in the residential histories. Using this information, we assigned yearly THM concentrations to each residence and workplace. For residences or workplaces with a private water supply or for which bottled water was the primary source, we assumed zero exposure to THMs.

Using these data in combination with other data derived from the study questionnaire, we created multiple THM exposure metrics. First, we created a time-weighted average THM concentration, which was calculated by summing the weighted THM concentrations for each year and dividing by the total number of years with an assigned THM value. The result represented the THM concentration in the water supplies to the home and, where applicable, the workplace combined. We estimated the proportion of water consumed from the home and workplace taps by using information that the participant provided on the percentage they typically consumed from the home tap during their usual adult lifetime, with the remainder assigned to the workplace where applicable. Second, we calculated an average daily THM ingestion by multiplying each participant’s average THM concentration by the amount of water that they reported consuming per day during their adult lifetime. Finally, we calculated cumulative THM ingestion by multiplying each participant’s average THM concentration by the amount of water that they reported consuming per day during their adult lifetime. Water utilities where participants lived provided historical information from the 1970s, including proportion of ground/surface source over the years, type of disinfectant, annual average THM levels in treated water (total and chloroform, bromodichloromethane, dibromochloromethane, and bromoform), annual average level of organic matter, pH, and temperature in raw water, chlorine dose since 1950, and year when chlorination started. Water source history and the year chlorination was initiated were available for 123 municipalities, accounting for 79% of the person-years accumulated by study participants. THM concentrations...
Table 1. Association between cumulative TTHM intake and bladder cancer risk by susceptibility allele status in the new England Bladder Cancer Study (Maine, New Hampshire, and Vermont), 2001–2004.

| Chromosome Location | Gene/region | SNP | Cumulative THM (mg) | Cases (n) | Controls (n) | ORb | 95% CI | p-Trend | p-Interaction |
|---------------------|-------------|-----|---------------------|-----------|-------------|------|--------|---------|--------------|
| 1p13.3              | GSTM1       | Null vs. present | 0–138.05 | 88 | 122 | Ref | | 0.85 | | |
|                     |             |                   | >138.05–398.33 | 79 | 132 | 0.82 | 0.55, 1.24 | 0.05 | | |
|                     |             |                   | >398.33–801.93 | 104 | 133 | 1.01 | 0.68, 1.50 | 0.05 | | |
|                     |             |                   | >801.93 | 87 | 105 | 1.02 | 0.68, 1.54 | 0.05 | | |
| 2q37.1              | UGT1A       | rs11892031 | 0–138.05 | 1 | 1 | — | — | 0.69 | | |
|                     |             |                   | >138.05–398.33 | 9 | 12 | 0.93 | 0.29, 2.96 | 0.65 | | |
|                     |             |                   | >398.33–801.93 | 15 | 18 | 0.98 | 0.35, 2.71 | 0.45 | | |
|                     |             |                   | >801.93 | 12 | 10 | 1.35 | 0.43, 4.19 | 0.29 | | |
| 3q26.2              | TERC        | rs10936599 | 0–138.05 | 14 | 17 | Ref | — | 0.36 | | |
|                     |             |                   | >138.05–398.33 | 9 | 12 | 0.93 | 0.29, 2.96 | 0.65 | | |
|                     |             |                   | >398.33–801.93 | 15 | 18 | 0.98 | 0.35, 2.71 | 0.45 | | |
|                     |             |                   | >801.93 | 12 | 10 | 1.35 | 0.43, 4.19 | 0.29 | | |
| 3q28                | TP63        | rs710521 | 0–138.05 | 9 | 19 | Ref | — | 0.95 | | |
|                     |             |                   | >138.05–398.33 | 12 | 25 | 1.17 | 0.39, 3.47 | 0.22 | | |
|                     |             |                   | >398.33–801.93 | 16 | 19 | 1.77 | 0.60, 5.19 | 0.19 | | |
|                     |             |                   | >801.93 | 11 | 23 | 1.04 | 0.34, 3.15 | 0.23 | | |
| 4p16.3              | TMEM129/FGFR3 | rs798766 | 0–138.05 | 145 | 174 | Ref | — | 0.81 | | |
|                     |             |                   | >138.05–398.33 | 146 | 182 | 0.91 | 0.66, 1.26 | 0.24 | | |
|                     |             |                   | >398.33–801.93 | 114 | 188 | 0.72 | 0.51, 1.00 | 0.25 | | |
|                     |             |                   | >801.93 | 138 | 153 | 0.97 | 0.70, 1.36 | 0.46 | | |
| 5p15.33             | TERT        | rs401681 | 0–138.05 | 37 | 49 | Ref | — | 0.71 | | |
|                     |             |                   | >138.05–398.33 | 43 | 58 | 0.99 | 0.54, 1.81 | 0.00 | | |
|                     |             |                   | >398.33–801.93 | 37 | 60 | 0.72 | 0.39, 1.34 | 0.00 | | |
|                     |             |                   | >801.93 | 37 | 47 | 0.94 | 0.50, 1.77 | 0.00 | | |
| 8p22                | NAT2        | rs1495741 | 0–138.05 | 74 | 98 | Ref | — | 0.14 | | |
|                     |             |                   | >138.05–398.33 | 92 | 108 | 1.05 | 0.69, 1.61 | 0.01 | | |
|                     |             |                   | >398.33–801.93 | 85 | 116 | 0.89 | 0.58, 1.36 | 0.07 | | |
|                     |             |                   | >801.93 | 99 | 86 | 1.31 | 0.85, 2.03 | 0.07 | | |
| 8q24.3              | PSCA        | rs2294008 | 0–138.05 | 60 | 84 | Ref | — | 0.96 | | |
|                     |             |                   | >138.05–398.33 | 65 | 77 | 1.11 | 0.68, 1.81 | 0.00 | | |
|                     |             |                   | >398.33–801.93 | 54 | 81 | 0.86 | 0.52, 1.41 | 0.06 | | |
|                     |             |                   | >801.93 | 53 | 64 | 1.07 | 0.64, 1.78 | 0.00 | | |
| 8q24.3              | PSCA        | rs2978974 | 0–138.05 | 84 | 117 | Ref | — | 0.32 | | |
|                     |             |                   | >138.05–398.33 | 83 | 114 | 1.00 | 0.66, 1.51 | 0.00 | | |
|                     |             |                   | >398.33–801.93 | 84 | 96 | 1.13 | 0.74, 1.73 | 0.00 | | |
|                     |             |                   | >801.93 | 77 | 80 | 1.27 | 0.78, 1.86 | 0.00 | | |
| 8q24.21             | 8q24       | rs9642880 | 0–138.05 | 50 | 90 | Ref | — | 0.06 | | |
|                     |             |                   | >138.05–398.33 | 58 | 78 | 1.25 | 0.75, 2.06 | 0.00 | | |
|                     |             |                   | >398.33–801.93 | 61 | 84 | 1.26 | 0.77, 2.07 | 0.00 | | |
|                     |             |                   | >801.93 | 73 | 71 | 1.59 | 0.97, 2.61 | 0.00 | | |
| 11p15.5             | LSP1        | rs907611 | 0–138.05 | 75 | 114 | Ref | — | 0.02 | | |
|                     |             |                   | >138.05–398.33 | 87 | 141 | 0.92 | 0.61, 1.38 | 0.00 | | |
|                     |             |                   | >398.33–801.93 | 86 | 97 | 1.31 | 0.85, 2.01 | 0.00 | | |
|                     |             |                   | >801.93 | 94 | 88 | 1.51 | 0.98, 2.33 | 0.00 | | |
| Chromosome location | Gene/region | SNP       | Cumulative THM (mg) | No risk allele | 1–2 risk alleles |
|---------------------|-------------|-----------|---------------------|----------------|------------------|
|                     |             |           | Cases | OR | 95% CI | p-Trend | Cases | OR | 95% CI | p-Trend | p-Interaction |
| 13q34               | MCF2L       | rs4907479 | 0–138.05 | 116 | 144 | Ref | — | 0.99 | 99 | 122 | Ref | — | 0.17 | 0.41 |
|                     |             |           | >138.05–398.33 | 118 | 161 | 0.87 | 0.61, 1.25 | 105 | 115 | 1.12 | 0.76, 1.66 |
|                     |             |           | >398.33–801.93 | 124 | 144 | 1.01 | 0.71, 1.45 | 96 | 115 | 0.99 | 0.67, 1.48 |
|                     |             |           | >801.93 | 112 | 130 | 0.96 | 0.66, 1.43 | 104 | 89 | 1.30 | 0.87, 1.96 |
| 18q12.3             | SLC14A2     | rs10775480/ rs10853535 | 0–138.05 | 59 | 74 | Ref | — | 0.39 | 159 | 201 | Ref | — | 0.10 | 0.18 |
|                     |             |           | >138.05–398.33 | 62 | 84 | 0.95 | 0.58, 1.56 | 172 | 198 | 1.04 | 0.77, 1.41 |
|                     |             |           | >398.33–801.93 | 63 | 78 | 0.93 | 0.57, 1.52 | 163 | 192 | 1.04 | 0.76, 1.41 |
|                     |             |           | >801.93 | 53 | 69 | 0.85 | 0.51, 1.42 | 170 | 155 | 1.27 | 0.92, 1.74 |
| 18q12.3             | SLC14A2     | rs7238033 | 0–138.05 | 59 | 75 | Ref | — | 0.37 | 157 | 198 | Ref | — | 0.07 | 0.15 |
|                     |             |           | >138.05–398.33 | 61 | 82 | 0.96 | 0.59, 1.57 | 168 | 196 | 1.03 | 0.76, 1.40 |
|                     |             |           | >398.33–801.93 | 59 | 78 | 0.87 | 0.53, 1.44 | 159 | 184 | 1.06 | 0.77, 1.44 |
|                     |             |           | >801.93 | 52 | 68 | 0.85 | 0.51, 1.43 | 170 | 151 | 1.29 | 0.94, 1.77 |
| 19q12               | CCNE1       | rs8102137 | 0–138.05 | 79 | 125 | Ref | — | 0.71 | 141 | 150 | Ref | — | 0.35 | 0.92 |
|                     |             |           | >138.05–398.33 | 100 | 119 | 1.26 | 0.84, 1.89 | 135 | 163 | 0.87 | 0.62, 1.22 |
|                     |             |           | >398.33–801.93 | 82 | 116 | 1.06 | 0.70, 1.60 | 144 | 156 | 0.93 | 0.67, 1.31 |
|                     |             |           | >801.93 | 99 | 108 | 1.27 | 0.84, 1.91 | 127 | 117 | 1.08 | 0.76, 1.54 |
| 20p12.2             | CCNE1       | rs6104690 | 0–138.05 | 32 | 44 | Ref | — | 0.28 | 181 | 220 | Ref | — | 0.71 | 0.39 |
|                     |             |           | >138.05–398.33 | 37 | 61 | 0.80 | 0.42, 1.50 | 184 | 210 | 1.04 | 0.78, 1.39 |
|                     |             |           | >398.33–801.93 | 39 | 48 | 1.00 | 0.52, 1.91 | 181 | 208 | 1.03 | 0.77, 1.38 |
|                     |             |           | >801.93 | 39 | 42 | 1.25 | 0.65, 2.42 | 176 | 177 | 1.07 | 0.79, 1.44 |
| 20p12.2             | CCNE1       | rs6108803 | 0–138.05 | 142 | 188 | Ref | — | 0.75 | 72 | 76 | Ref | — | 0.49 | 0.78 |
|                     |             |           | >138.05–398.33 | 153 | 198 | 0.97 | 0.71, 1.33 | 71 | 78 | 1.00 | 0.62, 1.61 |
|                     |             |           | >398.33–801.93 | 151 | 172 | 1.08 | 0.79, 1.50 | 69 | 85 | 0.86 | 0.53, 1.37 |
|                     |             |           | >801.93 | 146 | 163 | 1.06 | 0.76, 1.47 | 69 | 56 | 1.18 | 0.72, 1.95 |
| 22q13.1             | APOBEC3     | rs1014971 | 0–138.05 | 24 | 29 | Ref | — | 0.28 | 196 | 247 | Ref | — | 0.11 | 0.09 |
|                     |             |           | >138.05–398.33 | 22 | 34 | 0.68 | 0.31, 1.51 | 213 | 248 | 1.07 | 0.81, 1.40 |
|                     |             |           | >398.33–801.93 | 22 | 32 | 0.72 | 0.33, 1.60 | 205 | 240 | 1.03 | 0.78, 1.36 |
|                     |             |           | >801.93 | 19 | 35 | 0.56 | 0.25, 1.26 | 207 | 188 | 1.27 | 0.95, 1.68 |

Note: —, no data; CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism; Ref, reference; THM, trihalomethane; TTHM, total trihalomethane.

aValue for multiplicative interaction between THM level and the respective polymorphism.

bORs are adjusted for smoking status, region/state, age, and sex.
| Chromosome location | Gene/region | Average TTHM concentration | Cases | Controls | OR[^b] | 95% CI | p-Trend |
|---------------------|-------------|----------------------------|-------|----------|--------|--------|---------|
| 1p13.3              | GSTM1       | 0.8–8.0                    | 56    | 86       | Ref    | —      | 0.56    |
|                     |             | >8.0–26.0                  | 50    | 76       | 1.28   | 0.70, 2.31 | 0.11    |
|                     |             | >26.0–49                  | 74    | 89       | 1.77   | 0.95, 3.31 | 0.05    |
|                     |             | >49                       | 77    | 109      | 1.74   | 0.82, 3.69 | 0.05    |
| 3q26.2              | TERC        | rs10936599                 | 8     | 11       | Ref    | —      | 0.04    |
|                     |             | >8.0–26.0                  | 1     | 5        | 0.23   | 0.02, 2.55 | 0.08    |
|                     |             | >26.0–49                  | 12    | 9        | 2.04   | 0.53, 7.86 | 0.11    |
|                     |             | >49                       | 5     | 9        | 0.88   | 0.18, 4.31 | 0.11    |
| 3q28                | TP63        | rs710521                   | 10    | 9        | Ref    | —      | 0.31    |
|                     |             | >8.0–26.0                  | 11    | 15       | 1.08   | 0.30, 3.86 | 0.05    |
|                     |             | >26.0–49                  | 10    | 13       | 1.07   | 0.29, 4.02 | 0.19    |
|                     |             | >49                       | 11    | 6        | 2.88   | 0.62, 13.33 | 0.08    |
| 4p16.3              | TMEM120/    | rs798766                   | 93    | 107      | Ref    | —      | 0.08    |
|                     | TACC3/      | FGFR3                      | 92    | 115      | 1.24   | 0.74, 2.09 | 0.09    |
|                     |             | >26.0–49                  | 120   | 103      | 2.02   | 1.15, 3.57 | 0.09    |
|                     |             | >49                       | 105   | 117      | 2.09   | 1.01, 4.33 | 0.09    |
| 5p15.33             | TERT        | rs401681                   | 30    | 37       | Ref    | —      | 0.02    |
|                     |             | >8.0–26.0                  | 20    | 41       | 0.74   | 0.32, 1.69 | 0.09    |
|                     |             | >26.0–49                  | 41    | 37       | 2.01   | 0.90, 4.49 | 0.09    |
|                     |             | >49                       | 32    | 41       | 2.10   | 0.82, 5.35 | 0.09    |
| 8p22                | NAT2        | rs1495741                  | 50    | 63       | Ref    | —      | 0.28    |
|                     |             | >8.0–26.0                  | 40    | 61       | 1.19   | 0.61, 2.29 | 0.09    |
|                     |             | >26.0–49                  | 70    | 67       | 2.04   | 1.05, 3.95 | 0.09    |
|                     |             | >49                       | 59    | 75       | 1.79   | 0.80, 4.03 | 0.09    |
| 8q24.3              | PSCA        | rs2294008                  | 41    | 47       | Ref    | —      | 0.40    |
|                     |             | >8.0–26.0                  | 42    | 46       | 1.22   | 0.60, 2.49 | 0.09    |
|                     |             | >26.0–49                  | 57    | 51       | 1.65   | 0.80, 3.39 | 0.09    |
|                     |             | >49                       | 44    | 57       | 1.64   | 0.70, 3.86 | 0.09    |
| 8q24.3              | PSCA        | rs2978974                  | 57    | 66       | Ref    | —      | 0.04    |
|                     |             | >8.0–26.0                  | 55    | 62       | 1.30   | 0.70, 2.41 | 0.09    |
|                     |             | >26.0–49                  | 69    | 59       | 1.97   | 1.02, 3.80 | 0.09    |
|                     |             | >49                       | 63    | 74       | 1.72   | 0.78, 3.82 | 0.09    |
| 8q24.21             | 8q24        | rs9642880                  | 50    | 51       | Ref    | —      | 0.14    |
|                     |             | >8.0–26.0                  | 27    | 48       | 0.69   | 0.34, 1.41 | 0.09    |
|                     |             | >26.0–49                  | 48    | 44       | 1.77   | 0.87, 3.61 | 0.09    |
|                     |             | >49                       | 50    | 60       | 1.58   | 0.69, 3.64 | 0.09    |
| 11p15.5             | LSP1        | rs907611                   | 60    | 82       | Ref    | —      | 0.01    |
|                     |             | >8.0–26.0                  | 59    | 87       | 1.22   | 0.68, 2.21 | 0.09    |
|                     |             | >26.0–49                  | 77    | 73       | 2.47   | 1.30, 4.70 | 0.09    |
|                     |             | >49                       | 71    | 90       | 2.22   | 1.01, 4.86 | 0.09    |
| 13q34               | MCF2L       | rs4907479                  | 84    | 76       | Ref    | —      | 0.02    |
|                     |             | >8.0–26.0                  | 64    | 82       | 0.90   | 0.51, 1.61 | 0.09    |
|                     |             | >26.0–49                  | 104   | 81       | 1.69   | 0.92, 3.10 | 0.09    |
|                     |             | >49                       | 87    | 97       | 1.49   | 0.70, 3.17 | 0.09    |
| 18q12.3             | SLC14A2     | rs10775480/                | 47    | 51       | Ref    | —      | 0.05    |
|                     |             | rs10655355                 | 40    | 52       | 1.05   | 0.53, 2.07 | 0.09    |
|                     |             | >26.0–49                  | 56    | 59       | 1.58   | 0.78, 3.19 | 0.09    |
|                     |             | >49                       | 57    | 60       | 2.08   | 0.90, 4.82 | 0.09    |
### Table 2. (Continued.)

| Chromosome | Gene/region | SNP | Cases | Controls | Cases | Controls | Cases | Controls |
|------------|-------------|-----|-------|----------|-------|----------|-------|----------|
| 19q12      | CCNE1       | rs8102137 | 0     | 72       | 77    | 70       | 90    | 90       |
|            |             |      | 0.09  | 0.09     | 0.09  | 0.09     | 0.09  | 0.09     |
| 19q12      | CCNE1       | rs6108803 | 0     | 98       | 98    | 98       | 96    | 98       |
|            |             |      | 0.01  | 0.01     | 0.01  | 0.01     | 0.01  | 0.01     |
| 20p12.2    | APOBEC3     | rs1014971 | 0     | 58       | 58    | 58       | 58    | 58       |
|            |             |      | 0.09  | 0.09     | 0.09  | 0.09     | 0.09  | 0.09     |

Risks differed by exposure metric in each study, which precluded pooling the data (Table S2). Rather, we analyzed each study separately using the metric with the highest risk related to THM exposure.}

For both studies, a value of $TTHM = 0$ was assigned for drinking bottled water and for water from a private well. Multiple THM metrics were created in both studies, including a time-weighted lifetime average concentration (in micrograms per liter), created by summing weighted THM averages, and cumulative intake (in milligrams), which also accounted for the amount of water ingested. The exposure distributions of TTHM differed between the two studies, with New England reporting lower overall levels than Spain. This was due to both the lower concentrations in the public water utilities and the higher proportion of homes served by private wells in New England, which are usually not chlorinated.

We used data for 16 genetic variants identified as susceptibility markers for bladder cancer based on a genome-wide association study (GWAS) and meta-analysis and that showed evidence in these populations. A total of 6,911 cases and 11,814 controls of European descent were scanned on several versions of Illumina GWAS chips with additional TaqMan genotyping of top hits. The heterozygous glutathione S-transferase mu 1 ($GSTM1$; null/present) genotype in a subgroup of cases and controls was assigned using a TaqMan-based deletion detection assay (see Supplementary Tables 1 and 2 in Figueroa et al.25) A total of 13 single nucleotide polymorphisms (SNPs) and the $GSTM1$ null genotype achieved genome-wide significance with risk of bladder cancer ($p < 5 \times 10^{-8}$) and two SNPs showed suggestive evidence of association. These 16 variants were also used in two previous studies that assessed gene–environment interactions and occupational exposures. More information about the risk alleles of all 16 markers can be found in Table S3.

### Statistical Analysis

Tests for linear trend were calculated using a Wald test with the midpoint value of each exposure category treated as a continuous
| Gene/gene region | Gene/gene region | SNP | TTHM Quartile | Cases (n) | Controls (n) | OR \(^b\) | 95% CI | p-Trend | Cases (n) | Controls (n) | OR \(^b\) | 95% CI | p-Trend | p-Interaction \(^c\) |
|-----------------|-----------------|-----|---------------|----------|-------------|---------|-------|--------|----------|-------------|---------|-------|--------|--------------------|
| 1p13.3          | GSTM1           |     |               |          |             |         |       |        |          |             |         |       |        |                    |
|                 |                 |     | Null vs. present | 1        | 162         | 233     | Ref   | 0.69   | 275     | 304         | Ref   | 0.04 | 0.53   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 3q26.2          | TERC            | rs10936599 |               | 1        | 22          | 29      | Ref   | 0.21   | 388     | 441         | Ref   | 0.42 | 0.93   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 3q28            | TP63            | rs710521 |               | 1        | 21          | 32      | Ref   | 0.63   | 391     | 438         | Ref   | 0.26 | 0.93   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 4p16.3          | TMEM129/        | rs798766 |               | 1        | 268         | 314     | Ref   | 0.63   | 148     | 167         | Ref   | 0.01 | 0.19   |                    |
|                 | TACC3/          |       |               |          |             |         |       |        |          |             |         |       |        |                    |
|                 | FGFR3           |       |               |          |             |         |       |        |          |             |         |       |        |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 5p15.33         | TERT            | rs401681 |               | 1        | 77          | 96      | Ref   | 0.65   | 336     | 376         | Ref   | 0.31 | 0.18   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 8p22            | NAT2            | rs1495741 |              | 1        | 142         | 192     | Ref   | 0.13   | 275     | 288         | Ref   | 0.64 | 0.66   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 8q24.3          | PSCA            | rs2294008 |              | 1        | 114         | 146     | Ref   | 0.77   | 301     | 331         | Ref   | 0.14 | 0.79   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 8q24.3          | PSCA            | rs2978974 |              | 1        | 155         | 207     | Ref   | 0.07   | 257     | 273         | Ref   | 0.80 | 0.77   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 8q24.21         | 8q24            | rs9642830 |              | 1        | 113         | 168     | Ref   | 0.06   | 298     | 303         | Ref   | 0.94 | 0.58   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 11p15.5         | LSP1            | rs907611 |              | 1        | 153         | 225     | Ref   | 0.005  | 251     | 236         | Ref   | 0.22 | 0.02   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 13q34           | MCF2L           | rs409749 |              | 1        | 171         | 251     | 1.08  | 0.75   | 239     | 225         | 1.05  | 0.79 | 0.13   |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |
| 18q12.3         | SLC14A2         | rs10775480/ |          | 1        | 152         | 141     | Ref   | 0.29   | 289     | 339         | Ref   | 0.04 | 0.78   |                    |
|                 |                 | rs10853535 |              |          |             |         |       |        |          |             |         |       |        |                    |
|                 |                 |     |               |          |             |         |       |        |          |             |         |       |        |                    |

\(^a\) Calculated as the difference in the interaction term between the given allele status and the other allele status. \(^b\) OR: Odds Ratio. \(^c\) p-Interaction: p-value for the interaction term.
Table 3. Continued.

| Gene/gene region | SNP | Cases (n) | Controls (n) | OR (95% CI) | Cases (n) | Controls (n) | OR (95% CI) |
|------------------|-----|-----------|-------------|-------------|-----------|-------------|-------------|
| 19q12 CCNE1      | rs8102137 | 1   | 176 (225) | 0.95 (0.54, 1.69) | 2 | 172 (232) | 1.44 (0.77, 2.70) |
|                  |     | 2 | 192 (192) | 1.44 (0.77, 2.70) | 3 | 223 (248) | 1.27 (0.91, 1.77) |
|                  |     | 3 | 283 (277) | 1.21 (0.69, 2.12) | 4 | 301 (288) | 1.28 (0.84, 1.96) |
| 20p12.2 CCNE1    | rs6104690 | 1 | 50 (71) | — | 2 | 75 (93) | 1.19 (0.50, 2.84) |
|                  |     | 2 | 75 (78) | 1.19 (0.50, 2.84) | 3 | 75 (78) | 1.43 (0.77, 2.66) |
|                  |     | 3 | 393 (374) | 1.32 (0.79, 2.21) | 4 | 426 (430) | 1.17 (0.89, 1.54) |
| 20p12.2 CCNE1    | rs6108803 | 1 | 276 (342) | 0.55 (0.36, 0.87) | 2 | 287 (357) | 1.03 (0.81, 1.32) |
|                  |     | 2 | 318 (307) | 1.37 (0.83, 2.28) | 3 | 318 (307) | 1.37 (0.83, 2.28) |
|                  |     | 3 | 433 (420) | 1.29 (0.80, 2.06) | 4 | 485 (471) | 1.31 (1.03, 1.68) |
| 22q13.1 APOBEC3 | rs1014971 | 1 | 37 (52) | 0.67 (0.38, 1.18) | 2 | 34 (49) | 1.08 (0.38, 3.06) |
|                  |     | 2 | 43 (49) | 1.56 (0.32, 7.61) | 3 | 43 (49) | 1.56 (0.32, 7.61) |
|                  |     | 4 | 39 (63) | 0.90 (0.32, 2.51) | 5 | 39 (63) | 0.90 (0.32, 2.51) |

Note: —, no data. CI, confidence interval; OR, odds ratio; Ref, reference; SNP, single nucleotide polymorphism; TTHM, total trihalomethanes.

aValue for multiplicative interaction between THM level and the respective polymorphism.
bORs are adjusted for smoking status, region/state, age, and sex.

cNo association between THMs and bladder cancer risk among subjects with the GA or AA genotypes at this locus. In addition, as shown in Table 3 and Figure 1, when combined in meta-analysis, the OR in quartile 4 was statistically significant among those with the GG genotype (OR in quartile 4 = 1.66 (95% CI: 1.17, 2.34; p-trend = 0.005; p-interaction = 0.02).

Results

**Exposure Distribution and THM Associations**

As previously reported, the concentrations of TTHMs in Spain were higher [median average concentration = 26.0 µg/L, interquartile range (IQR): 8.0–49.0 µg/L] than in New England (median average concentration: 15.7 µg/L, IQR range: 6.8–26.8 µg/L).13,14 For average concentration, the OR in the fourth quartile of exposure in Spain was 1.5 (95% CI: 0.9, 2.3; p-trend = 0.04), whereas in New England it was 1.1 (95% CI: 0.8, 1.4; p-trend = 0.48; Table S2). For cumulative intake, in Spain the OR in the highest quartile was 0.9 (95% CI: 0.7, 1.3; p-trend = 0.9), whereas in New England it was 1.2 (95% CI: 0.9, 1.54; p-trend = 0.2).

**Interactions between Bladder Cancer Susceptibility Loci and THM Levels**

Overall, evidence of interaction between the susceptibility loci and THM levels on bladder cancer risk was limited. However, there was some evidence of interaction for other loci in the New England study, including rs1014971 at 22q13.1 (APOBEC3B associated with THM independence in the source population. To further evaluate the potential biological plausibility for the strongest finding with rs907611, we conducted additional analyses. First, we evaluated the effect of the SNP with the strongest evidence of interaction within each quartile of THM level within each study. Second, in the New England Study, we evaluated whether there was an interaction with ibuprofen use, which has been shown to reduce the risk of bladder cancer1 in the New England Study. Nonsteroidal anti-inflammatory (NSAID) use was too infrequent to evaluate in Spain. All analyses were conducted in SAS version 9.2 (SAS Institute Inc.).

In addition, we analyzed candidate markers—glutathione S-transferase theta 1 (GSTT1; classified as +/+ or +/− vs. −/−), glutathione S-transferase zeta 1 (GSTZ1), and cytochrome P450 family 2 subfamily E member 1 (CYP2E1)—for which statistically significant interactions with TTHMs have been reported in a previous analysis from the Spanish Bladder Cancer Study.24

variable in regression models. Each marker was coded as a binary variable, indicating the presence or absence of risk alleles. All models were adjusted for age, state/region, smoking (never, former, current), and sex. All statistical tests were two sided, and a p-value of 0.05 was considered to be significant. Tests for multiplicative interaction were used to assess whether the genotype odds ratios (ORs) within categories of THM exposure or, equivalently, THM ORs within genotype categories, differed significantly from each other. Interactions were also tested using the likelihood-ratio test to allow estimation of parameters under the assumption of genotype–THM independence in the source population. To further evaluate the potential biological plausibility for the strongest finding with rs907611, we conducted additional analyses. First, we evaluated the effect of the SNP with the strongest evidence of interaction within each quartile of THM level within each study. Second, in the New England Study, we evaluated whether there was an interaction with ibuprofen use, which has been shown to reduce the risk of bladder cancer1 in the New England Study. Nonsteroidal anti-inflammatory (NSAID) use was too infrequent to evaluate in Spain. All analyses were conducted in SAS version 9.2 (SAS Institute Inc.).

In addition, we analyzed candidate markers—glutathione S-transferase theta 1 (GSTT1; classified as +/+ or +/− vs. −/−), glutathione S-transferase zeta 1 (GSTZ1), and cytochrome P450 family 2 subfamily E member 1 (CYP2E1)—for which statistically significant interactions with TTHMs have been reported in a previous analysis from the Spanish Bladder Cancer Study.24

Results

**Exposure Distribution and THM Associations**

As previously reported, the concentrations of TTHMs in Spain were higher [median average concentration = 26.0 µg/L, interquartile range (IQR): 8.0–49.0 µg/L] than in New England (median average concentration: 15.7 µg/L, IQR range: 6.8–26.8 µg/L).13,14 For average concentration, the OR in the fourth quartile of exposure in Spain was 1.5 (95% CI: 0.9, 2.3; p-trend = 0.04), whereas in New England it was 1.1 (95% CI: 0.8, 1.4; p-trend = 0.48; Table S2). For cumulative intake, in Spain the OR in the highest quartile was 0.9 (95% CI: 0.7, 1.3; p-trend = 0.9), whereas in New England it was 1.2 (95% CI: 0.9, 1.54; p-trend = 0.2).

**Interactions between Bladder Cancer Susceptibility Loci and THM Levels**

Overall, evidence of interaction between the susceptibility loci and THM levels on bladder cancer risk was limited. However, there was one SNP with a suggestion of interaction in both the New England (Table 1) and Spanish (Table 2) studies, rs907611 at 11p15.5 (leukocyte-specific protein 1 (LSP1) region), although it was only statistically significant in New England. This SNP also demonstrated an increased risk in the highest quartile of exposure among subjects with the GG genotype in each study. In New England, the OR in quartile 4 = 1.51 (95% CI: 0.98, 2.33; p-trend = 0.02) and p-interaction for THM level and polymorphism = 0.01 (Table 1). In Spain, the OR in quartile 4 = 2.22 (95% CI: 1.01, 4.86; p-trend = 0.01) and p-interaction = 0.10 (Table 2). In contrast, there was no association between THMs and bladder cancer risk among subjects with the GA or AA genotypes at this locus. In addition, as shown in Table 3 and Figure 1, when combined in meta-analysis, the OR in quartile 4 was statistically significant among those with the GG genotype (OR in quartile 4 = 1.66 (95% CI: 1.17, 2.34; p-trend = 0.005; p-interaction = 0.02).

There was some evidence of interaction for other loci in the New England study, including rs1014971 at 22q13.1 (APOBEC3B
region) (Table 1). However, neither the trend (p-trend = 0.11) nor the test of interaction was significant (p-interaction = 0.09). In addition, rs798766 at 4p16.3 (TMEM129/TACC3/FGFR3 region) and rs9642880 at 8q24.21 both had a significant interaction in Spain individually (Table 2) or in meta-analysis (Table 3).

Further analyses focused on the interaction between rs907611 at 11p15.5 (LSP1 region), which has been shown to influence the level of circulating lymphocytes, and the NSAID ibuprofen. We observed that the greatest reduction in risk related to ibuprofen use occurred in those with the GG genotype (Table 4). We also observed that the risk effect of the rs907611-A allele was attenuated at high exposures to THMs in both the New England and Spanish studies (Table 5).

**Candidate Gene Interactions**

The results from the analyses of the previously reported candidate genes are presented in Table S4. The analyses failed to show consistent associations between the two studies.

**Discussion**

In this analysis, we report on potential risk modification of the relation between THM exposure and 16 loci associated with bladder cancer. Although there is evidence that N-acetyltransferase 1 (NAT1) also plays a role in bladder carcinogenesis, SNPs in NAT1 genotyped as part of our GWAS did not show strong evidence of association with bladder cancer risk and therefore is not presented in these results. We found the strongest evidence of such an association for rs907611 (LSP1 region), with a suggestion of interaction in both New England and Spain. We note that this SNP achieved genomewide significance in the GWAS (p = 4.11 × 10^-8). In each study, there was also evidence of exposure–response within the genetic strata. Interestingly, suggestive evidence of interaction with high risk occupation was identified for this SNP in these study populations (p-interaction = 0.01).

A clear strength of this analysis is the detailed exposure assessment, which included historical information from participants on their residences and workplaces, and combined with measurement, source and treatment data from individual utilities, allowed for the creation of lifetime estimates of THM exposure. THMs have been consistently linked with bladder cancer risk in several studies, as reviewed by Costet, but few have examined such associations with both high-quality exposure and genetic data. Despite these high-quality exposure assessments, a limitation includes the inability to pool data from the two studies because of the different exposure distributions of THMs, as well as exposure metrics showing risk in each study. Toxicologic evidence suggests that the brominated species may be more important for bladder cancer etiology, and an earlier analysis within the New England study suggested higher risk with these compounds. Unfortunately, we did not have the ability to classify brominated species for all public water utilities, limiting our assessment, which included historical information from participants on their residences and workplaces, and combined with measurement, source and treatment data from individual utilities, allowed for the creation of lifetime estimates of THM exposure. THMs have been consistently linked with bladder cancer risk in several studies, as reviewed by Costet, but few have examined such associations with both high-quality exposure and genetic data. Despite these high-quality exposure assessments, a limitation includes the inability to pool data from the two studies because of the different exposure distributions of THMs, as well as exposure metrics showing risk in each study. Toxicologic evidence suggests that the brominated species may be more important for bladder cancer etiology, and an earlier analysis within the New England study suggested higher risk with these compounds. Unfortunately, we did not have the ability to classify brominated species for all public water utilities, limiting our sample size and precluding evaluation of interaction between these potentially important chemicals and susceptibility loci. Although the major method of water disinfection was chlorination in both studies, the levels of brominated compounds were higher in Spain, where the median average concentration of brominated compound was 6.2 μg/L (IQR: 3.8–29.1 μg/L), whereas in New England the median was 0.97 μg/L (IQR:

**Table 4. Interaction between ibuprofen use and rs976011 in New England Bladder Cancer Study, 2001–2004.**

| Genotype     | Never Ibuprofen use | Non-regular / < 10 years use of ibuprofen | ≥ 10 years use of ibuprofen | p-Interaction |
|--------------|---------------------|------------------------------------------|-----------------------------|---------------|
|              | Cases/controls (n/n) | OR (95% CI)n | Cases/controls (n/n) | OR (95% CI)n | Cases/controls (n/n) | OR (95% CI)n |                   |
| GG           | 165/198             | 1.0 (Ref) | 169/223            | 0.977 (0.72, 1.32) | 10/27          | 0.40 (0.19, 0.88) | 0.28             |
| AA or AG     | 251/245             | 1.25 (0.94, 1.65) | 241/284           | 1.05 (0.79, 1.39) | 20/26          | 0.94 (0.49, 1.79) |                   |

Note: CI, confidence interval; OR, odds ratio; Ref, reference.

*ORs are adjusted for smoking status, region/state, age, and sex.
0.36–1.76 μg/L, which may have additionally limited our ability to detect gene–environment interactions.

Several DBPs are genotoxic or mutagenic, either alone or as part of a mixture.4 Although bladder cancer risk has been linked to exposure to TTHMs in these and other studies, this metric is likely a surrogate for the etiologic compound or compounds responsible for this excess. A further limitation of these analyses is the fact that we could create only historical estimates for THMs. These are the most common DBPs, but they may serve only as a surrogate for the true etiologic compound or compounds responsible for the bladder cancer associations. Chloroform is the only THM classified as Group 2B (possible carcinogen), but several HAAs are considered possible or reasonably anticipated to be human carcinogens by the IARC and the NTP.9,11 Finally, we were restricted to evaluating these potential interactions in the only two studies with both high-quality–exposure and GWAS data, leading to limited statistical power.

Despite these limitations, we observed a consistent pattern of interaction in the two studies with evidence of exposure–response within genetic strata based on rs907611 (LSP1 region). LSP1 has been shown to play a role in recruiting leukocytes to inflamed sites based on experimental models.29 Chronic inflammation is important in bladder cancer initiation and development.30 The highest bladder cancer risk was observed in individuals with the highest exposure to THMs and homozgyous carriers of the G-allele. Previously, rs907611-A was identified as a common risk allele in bladder cancer GWAS (32% in controls of European ancestry) compared with the G-allele.33 The rs907611-A allele has also been associated (p = 3.41 × 10−10) with reduced counts of lymphocytes in a genome-wide analysis of blood-cell traits in the general population.33 In contrast, individuals with the rs907611-GG genotype conceivably could have more lymphocytes both in circulation and as tissue infiltrates. These infiltrating lymphocytes provide better immune surveillance, which helps to eliminate cells with emerging mutations before they give rise to tumors, potentially contributing a protective effect to this genotype from bladder cancer. On the other hand, bladder tissue with increased lymphocyte infiltration might be prone to chronic inflammation, which is a risk factor for many cancers.42 Thus, a possible explanation for our findings is that increased exposure to THMs in individuals with rs907611-GG genotype leads to exacerbated inflammation33 and, in turn, elevated cancer risk. In this instance, one would predict that the risk effect of the rs9076611-A allele would be attenuated at high exposures to THMs, and we indeed observed this pattern in both the New England and Spanish studies. The consistency of association between both studies is intriguing and provides support for this interaction. This model might also predict that anti-inflammatory agents, which have been found to reduce the risk of bladder cancer,47 would exert their greatest effect in subjects carrying the rs907611-GG genotype. Interestingly, we observed this pattern for ibuprofen use in the New England study, with the greatest reduction in risk occurring in those with the GG genotype.

To our knowledge, this is the first evaluation of the interaction between ubiquitous exposure to DBPs and known or suspected bladder cancer susceptibility loci. Future studies should investigate the role of different THM and other DBP species in populations with higher exposures and explore underlying molecular mechanisms.

Acknowledgments
We acknowledge F.X. Real for his contributions to the conduct of the Spanish Bladder Cancer Study, as well as for his review of an earlier draft of this manuscript.

References
1. Antoni S, Ferlay J, Sjoerdomataram I, Znaor A, Jamal A, Bray F. 2017. Bladder cancer incidence and mortality: a global overview and recent trends. Eur J Cancer 71(1):98–108, PMID: 27307077, https://doi.org/10.1016/j.ejca.2016.06.010.
2. Silverman D, Koutros S, Figueroa J, Prokunina-Olsson L, Rothman N. 2018. Bladder cancer. In: Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. Thun MJ, ed. New York: Oxford Press, 977–996.
3. Rook J. 1974. Formation of haloforms during chlorination of natural waters. Water Treat Exam 23:234–243.
4. Richardson SD, Plewa MJ, Wagner ED, Schoeny R, Demarini DM. 2007. Occurrence, genotoxicity and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research. Mutat Res 636(1–3):178–242, PMID: 17880849, https://doi.org/10.1016/j.mrrev.2007.09.001.
5. Regli S, Chen J, Messner M, Elvowitz MS, Letkiewicz FJ, Pegram RA, et al. 2015. Estimating potential increased bladder cancer risk due to increased bromide concentrations in sources of disinfected drinking waters. Environ Sci Technol 49(22):13094–13102, PMID: 26489011, https://doi.org/10.1021/acs.est.5b03547.
6. Kelly KJ, Connelly E, Reinhold GA, Byrne M, Prezant DJ. 2002. Assessment of health effects in New York City firefighters after exposure to polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs): the Staten Island Transformer Fire Health Surveillance Project. Arch Environ Health 57(4):282–293, PMID: 12505094, https://doi.org/10.1016/S0003-9896(02)90114-1.
7. European Commission. 1998. Council directive 98/83/EC of 3 November 1998 on the quality of water intended for human consumption. Off J Eur Comm L 330:32–54.
8. IARC (International Agency for Research on Cancer). 1999. Re-Evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide. Lyon, France: IARC, 71(pt 1):1–315.
9. IARC. 2013. Some chemicals in industrial and consumer products, some food contaminants and flavourings, and water chlorination by-products. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC.
10. IARC. 2004. Some Drinking Water Disinfectants and Contaminants, Including Arsenic. Lyon, France: IARC, 84.
11. NTP (National Toxicology Program). 2021. Haloacetic acids found as water disinfection by-products (selected). In: Report on Carcinogens. 15th ed. Research Triangle Park, NC: National Toxicology Program, NIEHS. RoC Profile: Haloacetic Acids; 15th RoC 2021, [accessed 12 January 2022].
12. U.S. EPA (U.S. Environmental Protection Agency). 2001. Toxicological Review of Chloroform (CAS No. 67–66–3). EPA/635/R-01/001. Washington, DC: U.S. EPA. https://www.epa.gov/ Ofdrc/pdfs/00035r.pdf; [accessed 12 April 2020].
13. Cantor KP, Hoover R, Hartge P, Mason TJ, Silverman DT, Altman R, et al. 1987. Bladder cancer, drinking water source, and tap water consumption: a case–control study. J Natl Cancer Inst 79(6):1269–1279, PMID: 3480378.
14. Costet N, Villanueva CM, Jaaokkola JJK, Kogevinas M, Cantor KP, King WD, et al. 2011. Water disinfection by-products and bladder cancer: is there a European specificity? and meta-analysis of European case–control studies. Occup Environ Med 68(5):379–385, PMID: 21389011, https://doi.org/10.1136/oem.2010.062703.

15. Villanueva CM, Cantor KP, Grimailt JO, Malats N, Silverman D, Tardon A, et al. 2006. Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol 165(2):148–156, PMID: 17079692, https://doi.org/10.1093/aje/kwi264.

16. Beane Freeman LE, Cantor KP, Baris D, Nuckols JR, Johnson A, Colt JS, et al. 2017. Bladder cancer and water disinfection by-product exposures through multiple routes: a population-based case–control study (New England, USA). Environ Health Perspect 125(6):067010, PMID: 28636529, https://doi.org/10.1289/ehp.1299809.

17. Figueroa JD, Koutros S, Colt JS, Kogevinas M, Garcia-Closas M, Real FX, et al. 2015. Modification of occupational exposures on bladder cancer risk by common genetic polymorphisms. J Natl Cancer Inst 107(11):djv223, PMID: 26374428, https://doi.org/10.1093/jnci/djv223.

18. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. 2005. N-ras slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486):849–859, PMID: 16112301, https://doi.org/10.1016/S0140-6736(05)67137-1.

19. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marist CJ, et al. 2008. A case–control study of smoking and bladder cancer risk: emerging patterns over time. J Natl Cancer Inst 101(22):1563–1561, PMID: 19197915, https://doi.org/10.1093/jnci/djp361.

20. Villanueva CM, Cantor KP, Grimailt JO, Cañste- Vinyals G, Malats N, Silverman D, et al. 2006. Assessment of lifetime exposure to trihalomethanes through different routes. Occup Environ Med 63(4):272–277, PMID: 16556748, https://doi.org/10.1136/oem.2005.023069.

21. Nuckols JR, Beane Freeman LE, Lubin JH, Airola MS, Baris D, Ayotte JD, et al. 2011. Estimating water supply arsenic levels in the New England Bladder Cancer Study. Environ Health Perspect 119(9):1279–1285, PMID: 21421449, https://doi.org/10.1289/ehp.1002345.

22. DeSimonean R, Kacker R. 2007. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105–114, PMID: 16807131, https://doi.org/10.1016/j.cct.2006.04.004.

23. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, et al. 2014. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23(5):1387–1398, PMID: 24163127, https://doi.org/10.1093/hmg/ddt519.

24. Cantor KP, Villanueva CM, Silverman DT, Figueroa JD, Real FX, Garcia-Closas M, et al. 2010. Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect 118(11):1545–1550, PMID: 20675267, https://doi.org/10.1289/ehp.1002206.

25. Chen MH, Raffield LM, Moussas A, Sakaue S, Huffman JE, Moscati A, et al. 2020. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell 182(9):1198–1213.e14, PMID: 32200453, https://doi.org/10.1016/j.cell.2020.06.045.

26. El Kawak M, Dhaiah HR, Jabbour ME, Moussa MA, El Asmar K, Aoun M. 2020. Slow N-acetylation as a possible contributor to bladder carcinogenesis. Mol Carcinog 59(10):1077–1082, PMID: 32529781, https://doi.org/10.1002/mc.23232.

27. Cantor KP, Steinmans C, Ward MH, Beane Freeman LE. 2017. Water contaminants. In: Cancer Epidemiology and Prevention. Thun MJ, Linet MS, Cerhan JR, Haiman C, Schottenfeld D, 4th eds. New York: Oxford Press, 305–328.

28. Salas LA, Cantor KP, Tardon A, Serra C, Carrato A, Garcia-Closas R, et al. 2013. Biological and statistical approaches for modeling exposure to specific trihalomethanes and bladder cancer risk. Am J Epidemiol 178(4):652–660, PMID: 23648803, https://doi.org/10.1093/aje/kjt009.

29. Jongstra-Bilen J, Jongstra J. 2006. Leukocyte-specific protein 1 (LSP1): a regulator of leukocyte emigration in inflammation. Immunol Res 35(1–2):65–74, PMID: 17003510, https://doi.org/10.1385/IR:35:1:65.

30. Zheng YL, Amr S, Saleh DA, Dash C, Ezzat S, Mikhail NN, et al. 2012. Urinary bladder cancer risk factors in Egypt: a multicenter case–control study. Cancer Epidemiol Biomarkers Prev 21(3):537–546, PMID: 22147365, https://doi.org/10.1158/1055-9966.EPI-11-0589.

31. Kesler RM, Mayer A, Fent KW, Chen IC, Deaton AS, Ormond RB, et al. 2021. Effects of firefighting hood design, laundering and doffing on smoke protection, heat stress and wearability. Ergonomics 64(6):757–767, PMID: 33383449, https://doi.org/10.1080/00140139.2020.1867241.

32. Smyth MJ, Dunn GP, Schreiber RD. 2006. Cancer immunosurveillance and immunoeediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50, PMID: 16730260, https://doi.org/10.1016/S0065-2776(06)90001-7.

33. Das S, Kumar A, Seth RK, Tokar EJ, Kadiiska MB, Waalkes MP, et al. 2013. Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity. Toxicol Appl Pharmacol 269(3):297–306, PMID: 23438451, https://doi.org/10.1016/j.taap.2013.02.003.